Bolt Biotherapeutics, Inc.: Coastlands Capital LP discloses a stake of more than 5% (Schedule 13G)
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 6 November 2026, by SEC EDGAR SCHEDULE 13G
30
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Coastlands Capital LP disclosed a stake of more than 5% in Bolt Biotherapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001104659-26-123999). The filing signals a new or increased passive position in the clinical-stage immuno-oncology company by the institutional investor. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further detail in the full filing and any subsequent 13G amendments.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Bolt Biotherapeutics, Inc., Coastlands Capital LP